SG11201909652WA - Neoantigen identification, manufacture, and use - Google Patents

Neoantigen identification, manufacture, and use

Info

Publication number
SG11201909652WA
SG11201909652WA SG11201909652WA SG11201909652WA SG 11201909652W A SG11201909652W A SG 11201909652WA SG 11201909652W A SG11201909652W A SG 11201909652WA SG 11201909652W A SG11201909652W A SG 11201909652WA
Authority
SG
Singapore
Prior art keywords
international
gritstone
emeryville
suite
oncology
Prior art date
Application number
Other languages
English (en)
Inventor
Thomas Boucher
Brendan Bulik-Sullivan
Jennifer Busby
Roman Yelensky
Original Assignee
Gritstone Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gritstone Oncology Inc filed Critical Gritstone Oncology Inc
Publication of SG11201909652WA publication Critical patent/SG11201909652WA/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/40—Encryption of genetic data
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioethics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
SG11201909652W 2017-04-19 2018-04-19 Neoantigen identification, manufacture, and use SG11201909652WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762487469P 2017-04-19 2017-04-19
PCT/US2018/028438 WO2018195357A1 (en) 2017-04-19 2018-04-19 Neoantigen identification, manufacture, and use

Publications (1)

Publication Number Publication Date
SG11201909652WA true SG11201909652WA (en) 2019-11-28

Family

ID=63857025

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909652W SG11201909652WA (en) 2017-04-19 2018-04-19 Neoantigen identification, manufacture, and use

Country Status (14)

Country Link
US (1) US20210113673A1 (he)
EP (1) EP3612965A4 (he)
JP (2) JP7217711B2 (he)
KR (1) KR20190140935A (he)
CN (1) CN110636852A (he)
AU (2) AU2018254526B2 (he)
BR (1) BR112019021782A2 (he)
CA (1) CA3060569A1 (he)
CO (1) CO2019012345A2 (he)
IL (1) IL269855B2 (he)
MX (1) MX2019012433A (he)
RU (1) RU2019136762A (he)
SG (1) SG11201909652WA (he)
WO (1) WO2018195357A1 (he)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
SG11201804957VA (en) 2015-12-16 2018-07-30 Gritstone Oncology Inc Neoantigen identification, manufacture, and use
HUE065174T2 (hu) 2017-02-12 2024-05-28 Biontech Us Inc HLA-alapú módszerek és készítmények, valamint azok felhasználása
EP3651791A1 (en) * 2017-07-14 2020-05-20 The Francis Crick Institute Limited Analysis of hla alleles in tumours and the uses thereof
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
KR20200118029A (ko) 2018-01-04 2020-10-14 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
US20210181188A1 (en) * 2018-08-24 2021-06-17 The Regents Of The University Of California Mhc-ii genotype restricts the oncogenic mutational landscape
US10586164B1 (en) 2018-10-15 2020-03-10 AIble Inc. Interface for visualizing and improving model performance
US10936768B2 (en) * 2018-10-15 2021-03-02 Aible, Inc. Interface for visualizing and improving model performance
US20220125919A1 (en) * 2018-11-07 2022-04-28 Gritstone Bio, Inc. Alphavirus neoantigen vectors and interferon inhibitors
EP3906045A1 (en) 2019-01-03 2021-11-10 Evaxion Biotech ApS Vaccines targeting neoepitopes
CN111621564B (zh) * 2019-02-28 2022-03-25 武汉大学 一种鉴定有效肿瘤新抗原的方法
KR20210137110A (ko) * 2019-03-06 2021-11-17 그릿스톤 바이오, 인코포레이티드 Mhc 클래스 ii 모델을 사용한 신생항원 동정
AU2020234003A1 (en) 2019-03-11 2021-11-11 Evaxion Biotech A/S Nucleic acid vaccination using neo-epitope encoding constructs
WO2020185010A1 (ko) * 2019-03-12 2020-09-17 (주)신테카바이오 인공지능모델기반 분자동역학 빅데이터를 활용한 신생항원 면역치료정보 제공 시스템 및 방법
CA3138867A1 (en) * 2019-05-03 2020-11-12 Guilhem RICHARD Neoantigens in cancer
EP3993829A4 (en) * 2019-07-02 2024-01-03 Gritstone bio, Inc. HIV ANTIGENS AND MHC COMPLEXES
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
US20220334129A1 (en) 2019-09-13 2022-10-20 Evaxion Biotech A/S Method for identifying T-cell epitopes
EP4076507A1 (en) 2019-12-18 2022-10-26 Evaxion Biotech A/S Nucleic acid vaccination using neo-epitope encoding constructs
WO2021141374A1 (ko) * 2020-01-07 2021-07-15 한국과학기술원 신생항원을 스크리닝하는 방법, 시스템 및 그의 용도
US12094579B2 (en) * 2020-04-03 2024-09-17 Oregon State University Machine-learning method and apparatus to isolate chemical signatures
EP4132959A1 (en) 2020-04-07 2023-02-15 Evaxion Biotech A/S Neoepitope immunotherapy with apc targeting unit
WO2021257879A1 (en) * 2020-06-18 2021-12-23 Personalis Inc. Machine-learning techniques for predicting surface-presenting peptides
EP4181949A1 (en) 2020-07-14 2023-05-24 Evaxion Biotech A/S Apc targeting units for immunotherapy
EP4213158A1 (en) 2020-11-13 2023-07-19 Ahead Biocomputing, Co. Ltd Information processing device, information processing method, recording medium recording information processing program, and information processing system
CA3202466A1 (en) 2021-01-14 2022-07-21 Jiani LI Hiv vaccines and methods of using
JP7057003B1 (ja) 2021-02-26 2022-04-19 国立大学法人東京工業大学 予測装置、学習済みモデルの生成装置、予測方法、学習済みモデルの生成方法、予測プログラム、及び学習済みモデルの生成プログラム
JP7057004B1 (ja) 2021-03-05 2022-04-19 国立大学法人東京工業大学 予測装置、学習済みモデルの生成装置、予測方法、学習済みモデルの生成方法、予測プログラム、及び学習済みモデルの生成プログラム
CA3216276A1 (en) 2021-04-29 2022-11-03 Yardena Samuels T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same
CN113762416B (zh) * 2021-10-15 2023-05-30 南京澄实生物科技有限公司 基于多模态深度编码的抗原免疫原性预测方法和系统

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180730B (zh) * 2010-05-14 2016-03-02 综合医院公司 鉴定肿瘤特异性新抗原的组合物和方法
CA2908434C (en) * 2013-04-07 2021-12-28 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
SG11201804957VA (en) * 2015-12-16 2018-07-30 Gritstone Oncology Inc Neoantigen identification, manufacture, and use
US20190346442A1 (en) * 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
EP3600340A4 (en) * 2017-03-31 2021-01-20 ACT Genomics (IP) Co., Ltd. CLASSIFICATION SYSTEM FOR CANCER-SPECIFIC IMMUNOGENIC EPITOPES

Also Published As

Publication number Publication date
EP3612965A4 (en) 2021-01-13
AU2018254526B2 (en) 2024-02-15
CN110636852A (zh) 2019-12-31
IL269855B1 (he) 2023-01-01
IL269855A (he) 2019-11-28
WO2018195357A1 (en) 2018-10-25
JP2023055775A (ja) 2023-04-18
CO2019012345A2 (es) 2020-01-17
EP3612965A1 (en) 2020-02-26
RU2019136762A (ru) 2021-05-19
AU2024202903A1 (en) 2024-05-23
JP7530455B2 (ja) 2024-08-07
BR112019021782A2 (pt) 2020-08-18
AU2018254526A1 (en) 2019-11-14
JP2020519246A (ja) 2020-07-02
MX2019012433A (es) 2019-12-11
KR20190140935A (ko) 2019-12-20
US20210113673A1 (en) 2021-04-22
JP7217711B2 (ja) 2023-02-03
IL269855B2 (he) 2023-05-01
CA3060569A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
SG11201909652WA (en) Neoantigen identification, manufacture, and use
SG11201804957VA (en) Neoantigen identification, manufacture, and use
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201805217XA (en) Compositions and methods for the treatment of hemoglobinopathies
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201807538PA (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
SG11201810327XA (en) Single domain serum albumin binding protein
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201807025SA (en) Crispr/cas systems for c-1 fixing bacteria
SG11201806282XA (en) High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies
SG11201908847TA (en) Apparatuses, systems and methods for imaging flow cytometry
SG11201806639VA (en) New streptococcal proteases
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201809751XA (en) Egfr inhibitor compounds
SG11201906663VA (en) Bone-targeting antibodies
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201908296VA (en) Biomarkers for cancer therapeutics
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof